James D. Otvos,Irina Y. Shalaurova,Dennis W. Bennett,Justyna E. Wolak-Dinsmore
申请号：
US15264977
公开号：
US20170003269A1
申请日:
2016.09.14
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states . The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
